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Background
Kidney fibrosis is frequently observed in cardiorenal
diseases. Cyclic guanosine monophosphate (cGMP)
serves as the most important second messenger of
nitric oxide (NO) and has shown antifibrotic effects at
enhanced levels in several experimental models of kid-
ney diseases. Antifibrotic effects of cGMP signalling
via cGMP-dependent protein kinases (cGK), in particu-
lar cGKI, have already been shown. Serelaxin and
zaprinast are both able to increase cGMP signalling via
influencing two independent pharmacological targets.
Serelaxin is currently in phase III development for
acute heart failure and has shown antifibrotic proper-
ties in several in vitro and in vivo experiments. It
is discussed that serelaxin inhibits TGF-b signalling
via RXFP1 receptor. Involvement of NO / cGMP in
this process has also been revealed. Zaprinast is a
selective inhibitor of phosphodiesterase V, which leads
to enhanced levels of cGMP by blocking cGMP
degradation.
Purpose
The aim of the study was to compare renal antifibrotic
effects of the cGMP enhancing serelaxin and the
cGMP-degradation-limiting zaprinast in a model of
interstitial kidney fibrosis. We hypothesize that antifi-
brotic properties of both compounds are mediated
through cGMP dependent protein kinases, namely
cGKI.
Methods
Kidney fibrosis was induced by unilateral ureteral
obstruction (UUO) in wild type (WT) and cGKI knock
out (KO) mice. Serelaxin was administered through
osmotic minipumps (0.5 mg/kg/d) immediately after
UUO for seven days. Zaprinast was administered through
intraperitoneal injections once a day (10 mg/kg/d) imme-
diately after UUO for seven days. cGMP levels were mea-
sured via ELISA. Antifibrotic effects were assessed by
biomarkers indicating myofibroblast differentiation,
extracellular matrix (ECM) accumulation or degradation
via mRNA- and protein expression.
Results
The levels of cGMP were enhanced in kidney tissue after
treatment with Serelaxin or Zaprinast. In WT, Serelaxin
and Zaprinast significantly reduced renal interstitial fibro-
sis assessed by remodeling biomarkers, e.g. a-SMA, total
collagen, Col1a1, fibronectin and gelatinases. In contrast
to Zaprinast, Serelaxin showed no antifibrotic effects on
mRNA and protein expression of ECM accumulation in
cGKI-KO.
Conclusion
These results indicate that Serelaxin and Zaprinast have
comparable antifibrotic effects in the kidney of WT ani-
mals. The involvement of cGMP signalling through
cGKI was shown in both treatment options, e.g. regard-
ing myofibroblast differentiation. Due to reduced extra-
cellular matrix in cGKI-KO after Zaprinast treatment,
additional cGKI independent mechanisms are supposed
for antifibrotic signalling of Zaprinast.
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